Clinical trial
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
NCT00131261 · Valerio Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00131261 |
|---|---|
| Title | Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma |
| Official title | A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma |
| Lead sponsor | Valerio Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | PXD101, Dexamethasone |
| Enrollment | 25 |
| Start date | Jan 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Aug 18, 2005 |
| Last update posted | Jul 8, 2015 |
| Countries | Denmark, Norway, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: